New small molecules to block cancer growth and improve immune response
Official title: First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers
Funded at University of Maryland Baltimore · NIH-10999455 · Data updated 2026-11-12
This study is exploring new treatments for cancer that can block both the growth of cancer cells and help the immune system fight the disease, aiming to make therapies more effective and with fewer side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | December 11, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $639,330 |
| NIH project number | 5R01CA285468-02 |
| Project ID | NIH-10999455 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with various types of cancers who have not responded well to existing therapies.
✕Less likely to help
Patients with early-stage cancers that are easily treatable with standard therapies may not benefit from this research.
What this research studies
This research focuses on developing innovative small molecules that can inhibit protein translation and an immune checkpoint simultaneously in cancer cells. By targeting multiple pathways essential for cancer progression, the approach aims to reduce the risk of drug resistance and minimize toxicity to normal tissues. Patients may benefit from therapies that are more effective and have fewer side effects compared to traditional treatments. The research involves laboratory experiments and preclinical testing to evaluate the efficacy and safety of these new compounds.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with reduced side effects.
How similar studies have gone: Other research has shown promise in targeting multiple pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Carrier, France — University of Maryland Baltimore
- Study coordinator: Carrier, France
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.